share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Prasad Raju

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities

CRISPR Therapeutics | 4：持股变动声明
美股sec公告 ·  03/22 17:48
Moomoo AI 已提取核心信息
Raju Prasad, the Chief Financial Officer of CRISPR Therapeutics AG, was involved in a transaction with the company's stock on March 20, 2024. The specific details of the transaction, such as the action type, status, number of shares, nature of shares, transaction price, and post-transaction holdings, were not disclosed in the announcement. This information is critical for investors to understand the potential impact on their investment and the confidence of the company's executives in its future.
Raju Prasad, the Chief Financial Officer of CRISPR Therapeutics AG, was involved in a transaction with the company's stock on March 20, 2024. The specific details of the transaction, such as the action type, status, number of shares, nature of shares, transaction price, and post-transaction holdings, were not disclosed in the announcement. This information is critical for investors to understand the potential impact on their investment and the confidence of the company's executives in its future.
2024年3月20日，CRISPR Therapeutics AG的首席财务官拉朱·普拉萨德参与了与该公司股票的交易。公告中未披露交易的具体细节，例如行动类型、状态、股票数量、股票性质、交易价格和交易后持有量。这些信息对于投资者了解其投资的潜在影响以及公司高管对未来的信心至关重要。
2024年3月20日，CRISPR Therapeutics AG的首席财务官拉朱·普拉萨德参与了与该公司股票的交易。公告中未披露交易的具体细节，例如行动类型、状态、股票数量、股票性质、交易价格和交易后持有量。这些信息对于投资者了解其投资的潜在影响以及公司高管对未来的信心至关重要。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息